Part 2: Immunotherapies—A New Tool To Treat Methamphetamine Addiction? | National Institute on Drug Abuse (NIDA)
Source: Part 2: Immunotherapies—A New Tool To Treat Methamphetamine Addiction? | National Institute on Drug Abuse (NIDA)
read morePart 1: Immunotherapies—A New Tool To Treat Methamphetamine Addiction? | National Institute on Drug Abuse (NIDA)
Source: Part 1: Immunotherapies—A New Tool To Treat Methamphetamine Addiction? | National Institute on Drug Abuse...
read moreAs Deaths Rise, The Urgent Search For Medications To Treat Meth | CommonHealth
She [Nora Volkow] lays out the range of research for drugs to treat both the acute, overdose episodes and chronic treatment. To prevent an overdose, she says the U.S. government is funding trials of a drug that could be injected into someone dangerously high on meth....
read moreBinding Methamphetamine to Release People from Addiction
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 has received US FDA Fast Track Designation, and is being studied in an ongoing Phase 2 proof-of-concept study (STAMPOUT; NCT03336866). We are also developing a novel vaccine (IXT-v100) against methamphetamine, which is in Preclinical Development.
Part 2: Immunotherapies—A New Tool To Treat Methamphetamine Addiction? | National Institute on Drug Abuse (NIDA)
Source: Part 2: Immunotherapies—A New Tool To Treat Methamphetamine Addiction? | National Institute on Drug Abuse (NIDA)
read morePart 1: Immunotherapies—A New Tool To Treat Methamphetamine Addiction? | National Institute on Drug Abuse (NIDA)
Source: Part 1: Immunotherapies—A New Tool To Treat Methamphetamine Addiction? | National Institute on Drug Abuse...
read moreAs Deaths Rise, The Urgent Search For Medications To Treat Meth | CommonHealth
She [Nora Volkow] lays out the range of research for drugs to treat both the acute, overdose episodes and chronic treatment. To prevent an overdose, she says the U.S. government is funding trials of a drug that could be injected into someone dangerously high on meth....
read moreDeveloping Novel Therapeutics for Addiction
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 is being studied in an upcoming Phase 2 proof-of-concept study (STAMPOUT). We are also developing a novel vaccine (IXT-v100) against methamphetamine.